Egbert Tan
Psychiatry · Green Bay, WINPI 1245427111
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 27.4% of the total. Reporting peaked in 2019 at $1,076 and has fallen 65.1% since, to $375 in 2023. Among psychiatry clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 90 payments — averaging $35.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$867
- Alkermes, Inc.$588
- Neurocrine Biosciences, Inc.$437
- Teva Pharmaceuticals USA, Inc.$336
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$240
- AbbVie$190
- plus $507 from 9 others
What the payments were for
- Food & beverage$3,161100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $867 |
| Alkermes, Inc. | 12 | $588 |
| Neurocrine Biosciences, Inc. | 17 | $437 |
| Teva Pharmaceuticals USA, Inc. | 5 | $336 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $240 |
| AbbVie(2 entities) | 16 | $190 |
| Sunovion Pharmaceuticals Inc. | 1 | $111 |
| Johnson & Johnson | 3 | $99 |
| Vanda Pharmaceuticals Inc. | 5 | $96 |
| Indivior Inc. | 5 | $75 |
| Corium, LLC | 3 | $38 |
| Almatica Pharma LLC | 2 | $37 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$489
- REXULTI$229
- INGREZZA$226
- AUSTEDO$211
- ARISTADA INITIO$122
- LATUDA$111
- CAPLYTA$103
- ABILIFY MAINTENA$100
How this compares
$3,164 in reported general payments places this provider in the 90th percentile of 543 psychiatry providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 78 | $217,497 |
| AristadaAripiprazole Lauroxil | 40 | $113,245 |
| IngrezzaValbenazine Tosylate | 13 | $110,103 |
| VraylarCariprazine Hcl | 50 | $90,074 |
| Risperdal ConstaRisperidone Microspheres | 44 | $80,502 |
| Invega TrinzaPaliperidone Palmitate | 12 | $70,532 |
| PerserisRisperidone | 18 | $40,136 |
| RexultiBrexpiprazole | 22 | $35,827 |
| CaplytaLumateperone Tosylate | 17 | $27,939 |
| FanaptIloperidone | 17 | $26,366 |
| Aripiprazole | 194 | $16,589 |
| Clomipramine Hcl | 33 | $13,274 |
| Clozapine | 89 | $8,135 |
| Quetiapine Fumarate | 401 | $7,482 |
| Risperidone | 299 | $7,434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $867 | $253,324100 claims |
| Johnson & JohnsonRisperdal Consta, Invega Trinza | $99 | $151,03356 claims |
| Alkermes, Inc.Aristada | $588 | $113,24540 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $437 | $110,10313 claims |
| AbbVieVraylar | $190 | $90,07450 claims |
| Indivior Inc.Perseris | $75 | $40,13618 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $240 | $27,93917 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $96 | $26,36617 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $17 | $5,62215 claims |
| Almatica Pharma LLCSertraline Hcl | $37 | $2,652157 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 543 psychiatry providers in Wisconsin.
Other psychiatry in Green Bay
- David McMahonGreen Bay$6K
- Dhanvendran RamarGreen Bay$3K
- Emily RademacherGreen Bay$2K
- Scott WienerGreenfield$1.4M
- Joseph BergsRacine$346K
- Royle EenigenburgJuneau$344K
- Thomas IlicMilwaukee$324K
- Jay WinstonMilwaukee$238K
- Joseph BurgarinoMilwaukee$111K
- Sobia Kirmani MoeMadison$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.